Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 16/20 | 0.64 |
| ▸ | BCHE known ✓ | P06276 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7611649 | 0.99 | SLC6A2 (0.65) | SLC6A2BCHE | |
| SCHEMBL8946156 | 0.87 | SLC6A2 (0.49) | SLC6A2BCHE | |
| Hydrochloric Acid SCHEMBL7610845 | 0.86 | SLC6A2 (0.64) | SLC6A2 | |
| SCHEMBL7613274 | 0.85 | SLC6A2 (0.67) | SLC6A2 | |
| SCHEMBL7609679 | 0.84 | SLC6A2 (0.65) | SLC6A2 | |
| SCHEMBL8633973 | 0.84 | SLC6A2 (0.65) | SLC6A2 | |
| Hydrochloric Acid SCHEMBL8539619 | 0.84 | SLC6A2 (0.49) | SLC6A2BCHE | |
| SCHEMBL9203513 | 0.83 | SLC6A2 (0.64) | SLC6A2 | |
| Hydrochloric Acid SCHEMBL7617563 | 0.83 | SLC6A2 (0.64) | SLC6A2 | |
| SCHEMBL8546204 | 0.83 | SLC6A2 (0.50) | SLC6A2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678135-B1 | PROCESS FOR THE PREPARATION OF N-AMINO SUBSTITUTED HETEROCYCLIC COMPOUNDS | AVENTIS PHARMA INC (US) | 2009-05-13 | — | — | EP | disclosed |
| US-7112682-B2 | Process for the preparation of N-amino substituted heterocyclic compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20050101654-A1 | Process for the preparation of N-amino substituted heterocyclic compounds | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-12 | — | — | US | disclosed |
| EP-0635269-B1 | Use of N-(Pyridinyl)-1H-Indol-1-Amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders | HOECHST MARION ROUSSEL INC (US) | 1999-11-03 | — | — | EP | disclosed |
| US-5776955-A | Use of unsubstituted and substituted n-(pyrrol-1-yl)pyridinamines as anticonvulsant agents | HOECHST MARION ROUSSEL, INC. | 1998-07-07 | — | — | US | disclosed |
| EP-0635269-A1 | Use of N-(Pyridinyl)-1H-Indol-1-Amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1995-01-25 | — | — | EP | disclosed |
| EP-0287982-B1 | N-(Pyridinyl)-1H-indol-1-amines, a process for their preparation and their use as medicaments | HOECHST ROUSSEL PHARMA (US) | 1994-12-07 | — | — | EP | disclosed |
| US-5356910-A | Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1994-10-18 | — | — | US | disclosed |
| US-5039811-A | Analgesics, antidepressants, memory activators; condensation, reduction | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1991-08-13 | — | — | US | disclosed |
| US-4970218-A | ANALGESIC, ANTIDEPRESSANT, MEMORY ENHANCEMENT | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1990-11-13 | — | — | US | disclosed |
| US-4880822-A | COGNITION ACTIVATORS, ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1989-11-14 | — | — | US | disclosed |
| EP-0287982-A2 | N-(Pyridinyl)-1H-indol-1-amines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1988-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101654-A1 | Process for the preparation of N-amino substituted heterocyclic compounds | AADAT, KMO, KYNU | SLC6A2 675/4885BCHE 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.